Achillion Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Achillion has developed a platform based on Zinc Finger Targeting, a technology for directing drugs against viral sites that do not mutate and may therefore be less prone to becoming drug resistant. The company aims to produce novel therapies for HIV, hepatitis and other viruses. To balance the risks associated with exploiting such a nascent technology, Achillion has licensed several Yale University anti-viral compounds, one of which is already in the clinic.